2019 Volume 45 Issue 2 Pages 76-81
Recent reports have indicated that proton pump inhibitor (PPI) use affects serum magnesium levels, however few studies have investigated the relationship between PPI use and magnesium levels in peritoneal dialysis patients. This study aimed to clarify the association between PPI use and serum magnesium levels in peritoneal dialysis patients. We retrospectively reviewed the records of 27 patients who had received peritoneal dialysis in stable condition at the Aichi Prefectural Federation of Agricultural Cooperatives for Health and Welfare Kainan Hospital between August 2017 and July 2018. We defined hypomagnesemia as a value < 2.0 mg/dL, and they were divided into hypomagnesemia (n = 19) and non-hypomagnesemia (n = 8) groups according to the serum magnesium level. A comparison of the patient backgrounds in the two groups revealed significant differences in the serum magnesium levels and administration of PPI. Multiple logistic regression analysis showed that the administration of PPI (odds ratio: 8.50, 95％ confidence interval: 1.13-63.87, P = 0.038) was significantly related to hypomagnesemia. Therefore, the administration of PPI is a risk factor for the development of hypomagnesemia in peritoneal dialysis patients and should be used with caution, such as by monitoring serum magnesium for administration.
